Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

This study is ongoing, but not recruiting participants.
United States Department of Defense
Information provided by (Responsible Party):
Arteriocyte, Inc. Identifier:
First received: April 25, 2013
Last updated: April 12, 2017
Last verified: July 2016
This study will demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns. The study will be a randomized, double-blinded controlled safety study. Investigators expect that the PRP will deliver improved hemostasis and growth factors at the wound site thus increasing the effectiveness of treatment at the wound site. This will lead to rapid production and delivery of an autologous therapy that should minimize additional morbidity to the patient.

Condition Intervention Phase
Acute Burns
Device: Magellan®
Other: Placebo Saline Gel and Usual and Customary Standard of Care
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Care Provider, Investigator
Primary Purpose: Treatment
Official Title: Use of Autologous Platelet Rich Plasma (PRP) Gel as an Adjunct to the Treatment of Deep 2nd and 3rd Degree Burns

Resource links provided by NLM:

Further study details as provided by Arteriocyte, Inc.:

Primary Outcome Measures:
  • Demonstrate the safety of application of autologous platelet rich plasma (PRP) gel following excision of an acute deep 2nd and 3rd degree burn. [ Time Frame: 12 Months ]
    Examine that there is no increase in adverse events above what is seen with excision and split thickness autografting of deep 2nd and 3rd degree burns

Secondary Outcome Measures:
  • Assessment of a composite of wound healing measurements [ Time Frame: 12 Months ]

    This treatment is intended to stimulate rapid healing and improve outcomes of standard of care burn treatments:

    • Time to 100% healing and time to complete wound closure (skin re-epithelialization without drainage or dressing requirements confirmed at study visits wound remained closed for at least 14 days)
    • Length of hospital stay
    • Time for return to full activity clinical wound measurement with respect to wound surface area and need for reoperation.
    • Monitoring improvement of scar appearance.
    • Assessment of wound flora, dermal collagen and elastin content, and epithelialization using tissue markers.

Estimated Enrollment: 42
Study Start Date: April 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Autologous Platelet Rich Plasma (PRP)
Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
Device: Magellan®
Autologous Platelet Rich Plasma Prepared Using the Magellan System
Other Name: Autologous Platelet Rich Plasma
Placebo Comparator: Saline Gel, Standard of Care
Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
Other: Placebo Saline Gel and Usual and Customary Standard of Care

Detailed Description:
The goal of this study is to demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns. This treatment is intended to stimulate rapid healing and improve the outcome of standard of care treatments for burns common to active duty military personnel, and more broadly for treatment of all acute burns. The care is specific to excision and split thickness skin grafting in the context of this burn study. The study will enroll 42 patients receiving surgical management of acute 2nd and 3rd degree burns requiring excision and skin grafting. The patient's total body surface area burn injury should not exceed 20%. The study will be conducted for 12 months. This study will provide further information for the development of enhanced treatment of wound-deployable cellular therapy for advanced trauma care of burned warriors.

Ages Eligible for Study:   18 Years to 86 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent obtained either the subject or the subject's legally acceptable representative prior to screening activities
  • Male or female age ≥ 18 and ≤ 86 years of age
  • Total burn wound measuring ≤ 20% TBSA to include a deep partial thickness/full thickness area requiring surgical excision and autologous split thickness skin grafts
  • Hemoglobin HbA1c ≤7.5% (for patients with pre-existing diabetes mellitus)
  • Able and willing to comply with the procedures required by the protocol. Patients may be managed as either inpatient or outpatient.
  • If a female of childbearing potential, the subject must have a negative serum pregnancy test at screening
  • All participants, male and female, must use acceptable method(s) of birth control for the duration of the study
  • Female subjects must be of non-childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control):
  • Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry),
  • A partner who is physically unable to impregnate the subject (e.g., vasectomized)
  • Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to the patient's cell concentrate administration,
  • Intrauterine device (IUD)or,
  • Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)

Exclusion Criteria:

  • Conductive electrical burns and chemical burns
  • Digits, head, genitalia, palms of hands, soles of feet, and face are excluded as test sites
  • Burns that pose a risk to digits or limbs
  • Test area with infection as determined clinically by the investigator prior to surgery
  • Venous or arterial vascular disorder directly affecting a designated test area
  • Known immune deficiency disorder, either congenital or acquired
  • Chronically malnourished as determined clinically by the investigator prior to surgery (Investigators are responsible for determining subjects are chronically malnourished during the screening process. Investigators should take into consideration the following parameters: medical history and physical appearance, the subject's body mass index, and any significant laboratory findings)
  • Severe respiratory problems or concurrent head trauma at hospital admission, including inhalation injury requiring ventilatory support
  • Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study
  • Any other acute or chronic concurrent medical condition(s) that in the investigator's opinion are a contraindication to skin grafting and study participation or limit the participant's life expectancy to < 6 months
  • Known or suspected hypersensitivity to bovine protein
  • Concurrent participation in another clinical trial in which an investigational agent is used. (Subjects must not have been enrolled in another clinical trial within 30 days of enrolling in this trial)
  • Females who are pregnant or nursing or intend to become pregnant during the duration of the study
  • Burn wounds that occur over joints
  • Patients with the following abnormal laboratory test levels:
  • Stage 4 or greater chronic kidney disease (eGFR < 30 mL/min)
  • Hemoglobin < 10 g/dL
  • Thrombocytopenia < 100,000 platelets/µL
  • Serum albumin level <2.5 g/dL or > 30 g/dL at time of screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01843686

United States, California
University of California, Davis, Division of Burn Surgery
Sacramento, California, United States, 95817
United States, District of Columbia
Medstar Health Research Institute
Washington, District of Columbia, United States, 20010
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
Arteriocyte, Inc.
United States Department of Defense
Study Director: Brian R. Barnes, PhD Arteriocyte, Inc.
  More Information


Responsible Party: Arteriocyte, Inc. Identifier: NCT01843686     History of Changes
Other Study ID Numbers: ART-11-004
Study First Received: April 25, 2013
Last Updated: April 12, 2017

Keywords provided by Arteriocyte, Inc.:
Acute 2nd and 3rd Degree Burns
Autologous Platelet Rich Plasma (PRP)
Skin Grafting
Magellan® System

Additional relevant MeSH terms:
Wounds and Injuries processed this record on May 24, 2017